Status:
RECRUITING
Propofol vs Sevo for Paediatric Tumor Surgery
Lead Sponsor:
Hong Kong Children's Hospital
Collaborating Sponsors:
The University of Hong Kong
Conditions:
Solid Tumor
Carcinoma
Eligibility:
All Genders
6-18 years
Phase:
PHASE4
Brief Summary
Background: Retrospective studies and meta-analyses have shown a reduction in 5-year survival following inhalational based compared to propofol based total intravenous (TIVA) anaesthesia for cancer s...
Detailed Description
Surgical resection is the main modality of treatment for many solid tumors. Despite successful tumor resection, some patients develop local recurrence or metastasis, causing morbidities and mortality....
Eligibility Criteria
Inclusion
- patients coming for elective primary solid tumor resection for curative intent in Hong Kong Children's Hospital
- AND patients \> 5kg
- AND patients within age limit
Exclusion
- Autoimmune / Chronic inflammatory diseases e.g. Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) etc.
- Current Steroid therapy
- Surgery for tumour removal in the past year
- Allergy to Propofol
- intraoperative use of nitrous oxide
- Patient susceptible to Malignant Hyperthermia
- Patients / parents / legal guardians showing preference in anaesthetic techniques during recruitment process
Key Trial Info
Start Date :
January 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04475705
Start Date
January 11 2021
End Date
July 1 2028
Last Update
March 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hong Kong Children's Hospital
Hong Kong, Hong Kong